Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12951666 | 1.00 | ATM (0.60) | ATMSMN1; SMN2CYP3A4TSHRLMNA | |
| SCHEMBL21404926 | 1.00 | ATM (0.60) | ATMSMN1; SMN2CYP3A4TSHRLMNA | |
| SCHEMBL21469067 | 0.90 | ATM (0.68) | ATMCYP3A4TSHRLMNAALDH1A1 | |
| SCHEMBL8530402 | 0.90 | ATM (0.68) | ATMCYP3A4TSHRLMNAALDH1A1 | |
| SCHEMBL30460502 | 0.90 | ATM (0.68) | ATMCYP3A4TSHRLMNAALDH1A1 | |
| SCHEMBL18459501 | 0.89 | ATM (0.63) | ATMCYP3A4TSHRLMNAMEN1 | |
| SCHEMBL13721804 | 0.89 | ATM (0.63) | ATMCYP3A4TSHRLMNAMEN1 | |
| SCHEMBL13721922 | 0.89 | ATM (0.63) | ATMCYP3A4TSHRLMNAMEN1 | |
| SCHEMBL21399857 | 0.86 | ATM (0.60) | ATMCYP3A4TSHRLMNAMEN1 | |
| SCHEMBL2851560 | 0.86 | ATM (0.60) | ATMCYP3A4TSHRLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4537905-A2 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-3774789-B1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240076295-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2024-03-07 | — | — | US | disclosed |
| EP-4038066-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114787159-A | BRM targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-109071560-B | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | 瓦洛健康公司 | 2022-01-14 | — | — | CN | disclosed |
| WO-2021067606-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| CN-112166114-A | BRM targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2021-01-01 | — | — | CN | disclosed |
| US-10696665-B2 | Mutant IDH1 inhibitors | ELI LILLY AND COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696665-B2 | Mutant IDH1 inhibitors | IDH1, IDH3B, IDH3A | ATM 286/4885SMN1; SMN2 1388/4885CYP3A4 3737/4885 |
| US-20240076295-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | ATM 1167/4885SMN1; SMN2 588/4885CYP3A4 4860/4885 |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | IDH1, IDH3B, IDH3A | ATM 286/4885SMN1; SMN2 1388/4885CYP3A4 3737/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | ATM 1286/4885SMN1; SMN2 1205/4885CYP3A4 4848/4885 |
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | ATM 1167/4885SMN1; SMN2 588/4885CYP3A4 4860/4885 |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | ATM 1167/4885SMN1; SMN2 588/4885CYP3A4 4860/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | ATM 1704/4885SMN1; SMN2 1134/4885CYP3A4 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.